Compound: MEGESTROL ACETATE
SMILES: O=C1C=C2C(=C[C@H]3[C@H]4[C@]([C@@](OC(=O)C)(C(=O)C)CC4)(C)CC[C@@H]3[C@@]2(C)CC1)C
InChIKey: RQZAXGRLVPAYTJ-GQFGMJRRSA-N
Synonyms: MEGESTROL ACETATE, 595-33-5, Megestryl acetate, Megace, Niagestin, Megace ES, Megeron, Ovaban, Ovarid, Megestat, BDH 1298, Maygace, Pallace, Magestin, Volidan, SC 10363, NSC-71423, Megestil, Megesterol acetate, SC-10363, BDH-1298, 17alpha-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, 17alpha-Acetoxy-6-dehydro-6-methylprogesterone, 6-Dehydro-6-methyl-17alpha-acetoxyprogesterone, 6-Methyl-6-dehydro-17alpha-acetoxyprogesterone, SC10363, 17-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, TJ2M0FR8ES, 6-Methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate, DTXSID9040683, 17-Hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate, Pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-, 6-Methyl-3,20-dioxopregna-4,6-dien-17-yl acetate, 17alpha-Acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione, CHEBI:6723, DTXCID7020683, NSC71423, 6-Methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone, 6-Methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate, Acetate, Megestrol, Megestol, Megostat, ApoMegestrol, LinMegestrol, NuMegestrol, Apo Megestrol, Lin Megestrol, Nu Megestrol, (9beta,10alpha)-17-(Acetyloxy)-6-methylpregna-4,6-diene-3,20-dione, RefChem:55565, MEGESTROL 17alpha-ACETATE, Ovaban Tablets 20 mg, Ovaban Tablets 5 mg, 6-Dehydro-6-methyl-17 alpha-acetoxyprogesterone, 17 Alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione, 6-Methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione Acetate, 209-864-5, Megestrol-17-acetate, MFCD00056470, [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate, Megestrol 17.alpha.-acetate, 17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione, MLS000028633, MLS001074091, SMR000058691, Ovaban (Veterinary), Megestin, Megestrol acetate [USAN], (8xi,9xi,10xi,13xi,14xi)-6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate, CCRIS 372, Pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate, EINECS 209-864-5, UNII-TJ2M0FR8ES, Megestrol acetole [Progestins], Megestrol acetate [USAN:USP], Megestrol acetole, Megestrol-Acetate, 17-alpha-Acetoxy-6-dehydro-6-methylprogesterone, 6-Dehydro-6-methyl-17-alpha-acetoxyprogesterone, 6-Methyl-6-dehydro-17-alpha-acetoxyprogesterone, NCGC00016516-01, CAS-595-33-5, Nia, Megace (TN), 6-Methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione, Megestrol acetate CRS, 6-Methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate, 6-Methyl-6-dehydro-17.alpha.-acetylprogesterone, 6-Methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone, 6-Methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate, Medroxyprogesterone Acetate EP Impurity G, 17.alpha.-Acetoxy-6-dehydro-6-methylprogesterone, 6-Dehydro-6-methyl-17.alpha.-acetoxyprogesterone, 6-Methyl-6-dehydro-17.alpha.-acetoxyprogesterone, Megestrol acetate (USP), Opera_ID_1511, Prestwick0_000956, Prestwick1_000956, Prestwick2_000956, Prestwick3_000956, 6-Methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate, SCHEMBL745, Megestrol acetate (Standard), BSPBio_000952, MLS000759501, MLS001424055, par-100,2, SPBio_003101, MEGESTROL ACETATE [MI], BPBio1_001048, orb1309127, orb3025363, CHEMBL1201139, BDH1298, MEGESTROL ACETATE [VANDF], MSK2207, MEGESTROL ACETATE [MART.], HMS1570P14, HMS2051I20, HMS2090N04, HMS2097P14, HMS2235D16, HMS3714P14, MEGESTROL ACETATE [USP-RS], MEGESTROL ACETATE [WHO-DD], MEGESTROL ACETATE [WHO-IP], Tox21_110469, Tox21_302360, EBC-17082, HY-13676R, LMST02030118, MSK2207-100A, s1304, AKOS015894927, MEGESTROL ACETATE [GREEN BOOK], MSK2207-1000A, Tox21_110469_1, CCG-100899, CS-2065, DB00351, FM25040, MEGESTROL ACETATE [ORANGE BOOK], NC00149, MEGESTROL ACETATE [EP MONOGRAPH], 17-Acetoxy-6-methylpregna-4,20-dione, MEGESTROL ACETATE [USP MONOGRAPH], NCGC00024196-03, NCGC00024196-05, NCGC00255456-01, (1R,3aS,3bR,9aR,9bS,11aS)-1-acetyl-5,9a,11a-trimethyl-7-oxo-1H,2H,3H,3aH,3bH,7H,8H,9H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-1-yl acetate, AC-24570, AS-13384, HY-13676, SY076369, 17.alpha.-Acetoxy-6-methyl-4,20-dione, AB00490013, Megestrol acetate for system suitability CRS, NS00009122, Megestrol acetate for peak identification CRS, 17-Hydroxy-6-methylpregna-4,20-dione acetate, 17.alpha.-Acetoxy-6-methylpregna-4,20-dione, C08151, D00952, D91560, AB00383046-13, AB00383046-14, AB00383046-15, AB00383046_16, EN300-7480847, Pregna-4,20-dione, 17-(acetyloxy)-6-methyl-, SR-01000000258, Megestrol-17-acetate 100 microg/mL in Acetonitrile, Pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate, Q6808975, SR-01000000258-4, 17-(Acetyloxy)-6-methypregna-4,6-diene-3,20-dione, BRD-K19507340-001-03-1, BRD-K19507340-001-22-1, MEDROXYPROGESTERONE ACETATE IMPURITY G [WHO-IP], Megestrol acetate Solution in Acetonitrile, 1000ug/mL, Megestrol acetate Solution in Acetonitrile, 100ug/mL, Megestrol acetate, VETRANAL(TM), analytical standard, 17alpha-Acetoxy-6-methyl-4,6-pregnadiene-3,20-dione, Megestrol acetate, analytical standard, for drug analysis, MEDROXYPROGESTERONE ACETATE IMPURITY G [EP IMPURITY], WLN: L E5 B666 OV KU MUTJ A1 E1 FV1 FOV1 L1, 6-Methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate, Megestrol Acetate Working Standard (Secondary Reference Standard), Megestrol acetate, European Pharmacopoeia (EP) Reference Standard, 6-METHYL-3,20-DIOXOPREGNA-4,6-DIEN-17-YL ACETATE [WHO-IP], Megestrol acetate, United States Pharmacopeia (USP) Reference Standard, Megesgtrol Acetate, Pharmaceutical Secondary Standard; Certified Reference Material, Megestrol acetate for peak identification, European Pharmacopoeia (EP) Reference Standard, Megestrol acetate for system suitability, European Pharmacopoeia (EP) Reference Standard, (8R,9S,10R,13S,14S,17R)-17-Acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylacetat, Megace; Ovaban; (8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl acetate
Theoretical properties:
molecular_formula: C24H32O4
molecular_weight: 384.5 g/mol
exact_mass: 384.23005950 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 3
heavy_atom_count: 28
topological_polar_surface_area: 60.4 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 218.0-220.0 °C
Descriptions:
{"pubchem": "Megestrol Acetate can cause cancer and developmental toxicity according to state or federal government labeling requirements.", "chebi": "A steroid ester resulting from the formal condensation of the hydroxy group of megestrol with the carboxy group of acetic acid. It is an appetite stimulant used for the treatment of anorexia and cachexia. Also used for birth control and for the treatment of breast cancer.", "chembl": "MEGESTROL ACETATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.", "wikipedia": "Megestrol acetate (MGA), sold under the brand name Megace among others, is a progestin medication which is used mainly as an appetite stimulant to treat wasting syndromes such as cachexia. It is also used to treat breast cancer and endometrial cancer, and has been used in birth control. Megestrol acetate is generally formulated alone, although it has been combined with estrogens in birth control formulations. It is usually taken by mouth.\nSide effects of megestrol acetate include increased appetite, weight gain, vaginal bleeding, nausea, edema, low sex hormone levels, sexual dysfunction, osteoporosis, cardiovascular complications, glucocorticoid effects, and others. Megestrol acetate is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It has weak partial androgenic activity, weak glucocorticoid activity, and no other important hormonal activity. Due to its progestogenic activity, megestrol acetate has antigonadotropic effects. The mechanism of action of the appetite stimulant effects of megestrol acetate is unknown.\nMegestrol acetate was discovered in 1959 and was introduced for medical use, specifically in birth control pills, in 1963. It may be considered a \"first-generation\" progestin. The medication was withdrawn in some countries in 1970 due to concerns about mammary toxicity observed in dogs, but this turned out not to apply to humans. Megestrol acetate was approved for the treatment of endometrial cancer in 1971 and wasting syndromes in 1993. It is marketed widely throughout the world. It is available as a generic medication."}